NCT06058234 Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
| NCT ID | NCT06058234 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centers for Medicare and Medicaid Services/ Coverage and Analysis Group |
| Condition | Mild Alzheimer's Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 8,680 participants |
| Start Date | 2023-07-06 |
| Primary Completion | 2028-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 8,680 participants in total. It began in 2023-07-06 with a primary completion date of 2028-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).
Eligibility Criteria
Inclusion Criteria: * Medicare patients with a clinical diagnosis of mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD. Exclusion Criteria: * none
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06058234 clinical trial?
This trial is open to participants of all sexes, studying Mild Alzheimer's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06058234 currently recruiting?
Yes, NCT06058234 is actively recruiting participants. Contact the research team at CMS_caginquiries@cms.hhs.gov for enrollment information.
Where is the NCT06058234 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT06058234 clinical trial?
NCT06058234 is sponsored by Centers for Medicare and Medicaid Services/ Coverage and Analysis Group. The trial plans to enroll 8,680 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.